Research programme: CNS therapeutics - Plex Pharmaceuticals
Latest Information Update: 12 Aug 2016
At a glance
- Originator Plex Pharmaceuticals
- Class Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors; Tumour necrosis factor receptor-associated peptide and protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Glioblastoma; Parkinson's disease